Literature DB >> 26942572

Estimates and determinants of HPV non-vaccination and vaccine refusal in girls 12 to 14 y of age in Canada: Results from the Childhood National Immunization Coverage Survey, 2013.

Nicolas L Gilbert1,2, Heather Gilmour3, Ève Dubé4, Sarah E Wilson5,6,7, Julie Laroche1.   

Abstract

Since the introduction of HPV vaccination programs in Canada in 2007, coverage has been below public health goals in many provinces and territories. This analysis investigated the determinants of HPV non-vaccination and vaccine refusal. Data from the Childhood National Immunization Coverage Survey (CNICS) 2013 were used to estimate the prevalence of HPV non-vaccination and parental vaccine refusal in girls aged 12-14 years, for Canada and the provinces and territories. Multivariate logistic regression was used to examine factors associated with non-vaccination and vaccine refusal, after adjusting for potential confounders. An estimated 27.7% of 12-14 y old girls had not been vaccinated against HPV, and 14.4% of parents reported refusing the vaccine. The magnitude of non-vaccination and vaccine refusal varied by province or territory and also by responding parent's country of birth. In addition, higher education was associated with a higher risk of refusal of the HPV vaccine. Rates of HPV non-vaccination and of refusal of the HPV vaccine differ and are influenced by different variables. These findings warrant further investigation.

Entities:  

Keywords:  HPV; canada; coverage; determinants; vaccine

Mesh:

Substances:

Year:  2016        PMID: 26942572      PMCID: PMC4964714          DOI: 10.1080/21645515.2016.1153207

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


Introduction

Human papillomavirus (HPV) infections are associated with a range of health outcomes, including anogenital warts and cancers (vaginal, vulvar, penile, anal), in addition to a subset of head and neck squamous cell carcinomas. HPV vaccine recommendations were first issued in Canada in 2007 by the National Advisory Committee on Immunization (NACI) and publicly-funded programs targeting pre-adolescent females began in select Canadian provinces and territories the same year. By 2010, all jurisdictions included the HPV vaccine within their publicly-funded immunization schedules for females, with some of them offering catch-up programs. Following a recommendation by NACI in 2012, some jurisdictions have expanded their programs to also include boys. The Canadian Immunization Committee (CIC) recommended that 80% and 90% of eligible girls receive the required doses of HPV vaccine within 2 and 5 y of program introduction, respectively. The coverage necessary to achieve herd immunity effects for HPV remains uncertain, but a recent systematic review and meta-analysis suggest the presence of herd effects in high-income countries with female HPV vaccination coverage of at least 50%. Since HPV vaccination programs were introduced in Canada, uptake has been influenced by factors including limited knowledge or understanding of HPV and the diseases it causes, beliefs and concerns about the risk of side effects or that monogamous individuals do not need the vaccine. In British Columbia7and Quebec, concerns regarding HPV vaccine safety were cited by parents as a factor in vaccine decision-making. In Canada, delivery of immunization programs is the responsibility of provinces and territories, and therefore programs vary by jurisdiction. HPV immunization programs are primarily school–based in all jurisdictions and the target age group ranges from grade 4 to 8 (approximately ages 8 to 13 years). Canadian coverage estimates demonstrate heterogeneity in uptake across the country. In the province of Ontario, where school-based HPV immunization of grade 8 girls began in the 2007–2008 school year, 3-dose HPV vaccine coverage has risen over time, from only 51% in the first year of the program to 80% in the 2012–2013 school year. In a survey of 2,025 parents of grade-6 girls in British Columbia in 2008–2009, 65% reported that their daughters had received at least their first dose of HPV vaccine. A higher uptake was reported in Québec, where in a survey of 774 parents of 9- to 10-year-old girls, 88% of respondents reported agreeing to have their daughter receive the HPV vaccine. Finally, in Prince Edward Island in 2013, 85% of grade-6 girls had received 3 doses of the HPV vaccine. In comparison, in the United States, where the HPV vaccine is delivered primarily by healthcare providers outside the school setting, 3-dose coverage of girls aged 13–17 was 38% in 2013. Analyses of the 2013 Childhood National Immunization Coverage Survey (CNICS) data were undertaken to assess rates and determinants of HPV non-immunization and of parental refusal of the vaccine in a nationally representative sample of Canadian girls aged 12 to 14 y.

Results

The response rate (individuals agreeing to participate / individuals selected from the sampling frame) for parents or guardians of girls aged 12–14 was 60.4%, yielding an analytical sample of 5720 respondents. An estimated 27.7% (95% CI 25.8–29.6) of 12 to 14 y old girls had not received any dose of the HPV vaccine. Provincial and territorial non-vaccination rates ranged from 10.9% in Newfoundland and Labrador to 47.6% in Northwest Territories (Table 1). Nunavut and the Northwest Territories had non-vaccination rates significantly higher than all other provinces and territories, and the rate of non-vaccination in Newfoundland was significantly lower than in most other jurisdictions. Independent risk factors for not being vaccinated, determined by multiple logistic regression, were being aged 12 or 13 compared to 14, living in Ontario or further west or in one of the 3 territories compared to Prince Edward Island, and responding parent born in a country in the Americas other than Canada, or in Europe (compared to born in Canada). Non-vaccination decreased with age, which may be explained by catch-up programs.
Table 1.

Association between sociodemographic variables and not being vaccinated against HPV in 12–14-year girls, Canada, 2013.

 nRate (95% CI) Unadjusted OR (95% CI)pAdjusted OR (95% CI)p
Overall572027.7 (25.8–29.6)     
Age (years)       
  12172328.9 (26.0–31.8) 1.22 (0.98–1.52)0.0741.46 (1.16–1.83)0.001
  13200729.7 (26.4–33.1) 1.27 (1.01–1.60)0.0401.31 (1.03–1.67)0.026
  14199025.0 (21.9–28.0) Reference   
Province or territory       
  Newfoundland and Labrador52710.7 (8.1–13.3) 0.63 (0.43–0.93)0.0190.64 (0.43–0.94)0.022
  Prince Edward Island33515.9 (12.5–19.2) Reference Reference 
  Nova Scotia56321.1 (17.7–24.5) 1.42 (1.02–1.97)0.0381.35 (0.97–1.89)0.075
  New Brunswick48618.5 (15.0–22.0) 1.20 (0.86–1.69)0.2811.15 (0.82–1.62)0.429
  Quebec65220.3 (17.2–23.4) 1.35 (0.99–1.85)0.0551.25 (0.91–1.71)0.174
  Ontario40532.4 (27.6–37.1) 2.54 (1.84–3.51)<0.0012.42 (1.72–3.40)<0.001
  Manitoba50034.8 (30.6–39.0) 2.83 (2.08–3.86)<0.0012.59 (1.89–3.57)<0.001
  Saskatchewan50423.9 (20.0–27.8) 1.66 (1.20–2.30)0.0021.60 (1.14–2.23)0.006
  Alberta57129.2 (25.5–32.9) 2.19 (1.61–2.96)<0.0012.03 (1.49–2.76)<0.001
  British Columbia49032.4 (28.2–36.7) 2.55 (1.86–3.48)<0.0012.20 (1.58–3.05)<0.001
  Yukon26435.7 (32.7–38.7) 2.94 (2.22–3.91)<0.0012.65 (1.98–3.54)<0.001
  Northwest Territories25747.6 (43.6–51.6) 4.82 (3.61–6.46)<0.0014.62 (3.43–6.23)<0.001
  Nunavut16647.4 (42.0–52.9) 4.79 (3.44–6.66)<0.0014.68 (3.36–6.53)<0.001
Place of Birth       
  Canada516126.5 (24.5–28.5) Reference Reference 
  Americas (outside Canada)9135.2 (22.8–47.6)A1.51 (0.86–2.64)0.1541.14 (0.58–2.23)0.709
  Europe6345.4 (28.0–62.9)A2.31 (1.10–4.82)0.0261.33 (0.55–3.22)0.531
  Africa6221.1 (9.6–32.6)A0.74 (0.36–1.54)0.4220.73 (0.24–2.19)0.569
  Asia25936.6 (27.7–45.4) 1.60 (1.07–2.39)0.0221.45 (0.88–2.38)0.142
  Oceania/other/not stated8438.4 (23.0–53.7)A1.73 (0.88–3.40)0.1131.57 (0.55–4.55)0.402
Education of respondingparent       
  Secondary or less192728.3 (25.1–31.5) 1.00 (0.79–1.27)0.985  
  Post-secondary200326.2 (23.0–29.3) 0.90 (0.70–1.14)0.375  
  University graduate159828.3 (24.7–32.0) Reference   
Total household income       
  0 - $19,99935826.2 (19.2–33.2) 1.01 (0.69–1.50)0.947  
  $20,000 - $39,99977029.7 (24.7–34.8) 1.21 (0.92–1.59)0.181  
  $40,000 - $59,00078631.3 (26.1–36.5) 1.30 (0.99–1.71)0.061  
  $60,000 - $79,99984928.4 (23.6–33.1) 1.13 (0.86–1.48)0.370  
  $80,000 or more295726.0 (23.4–28.5) Reference   
Country of birth of responding parent       
  Canada462324.7 (22.6–26.8) Reference Reference 
  Americas (outside Canada)18537.3 (27.7–46.9) 1.81 (1.17–2.79)0.0071.69 (1.03–2.77)0.037
  Europe17250.7 (39.5–61.9) 3.13 (1.96–5.01)<0.0012.66 (1.58–4.49)<0.001
  Africa10726.0 (15.6–36.4)A1.07 (0.61–1.88)0.8191.23 (0.55–2.75)0.620
  Asia47032.2 (26.2–38.1) 1.45 (1.07–1.95)0.0161.06 (0.73–1.54)0.754
  Oceania/other/not stated/ respondent not a parent16334.5 (23.6–45.5)A1.61 (0.97–2.67)0.0671.34 (0.60–3.02)0.475

Rates and odds ratios are weighted (see methods)

Adjusted OR: adjusted for all variables shown in the column

A: coefficient of variation between 16.5% and 33%; interpret with caution

Association between sociodemographic variables and not being vaccinated against HPV in 12–14-year girls, Canada, 2013. Rates and odds ratios are weighted (see methods) Adjusted OR: adjusted for all variables shown in the column A: coefficient of variation between 16.5% and 33%; interpret with caution Compared to non-vaccination, the proportion of parents who refused the HPV vaccine for their daughter was lower, at 14.4% (95% CI 13.0–15.9) (Table 2). Refusal ranged from 2.9% to 17.9%, with Newfoundland and Labrador (2.9%) being significantly lower than in all other provinces or territories. Among parents of girls who had received at least one dose of the HPV vaccine, 1.5% (95% CI 1.0–2.0) reported having ever refused the vaccine. Fifty percent (50.0%, 95% CI 45.9–54.1) of parents of unvaccinated girls reported having refused the vaccine for their daughter.
Table 2.

Association between sociodemographic variables and parental refusal of HPV vaccination in 12–14-year girls, Canada, 2013.

 nRate (95% CI) Unadjusted OR (95% CI)pAdjusted OR (95% CI)p
Overall559514.4 (13.0–15.9)     
Age (years)       
  12168313.6 (11.3–15.9) 0.93 (0.70–1.24)   
  13197214.9 (12.4–17.4) 1.04 (0.78–1.37)   
  14194014.4 (12.0–16.9) Reference   
Province or territory       
  Newfoundland and Labrador5252.9 (1.5–4.3)A0.28 (0.16–0.51)<0.0010.31 (0.17–0.56)<0.001
  Prince Edward Island33112.3 (9.2–15.4) 1.34 (0.89–2.02)0.1631.37 (0.90–2.07)0.144
  Nova Scotia5589.5 (7.0–12.0) Reference Reference 
  New Brunswick48411.8 (8.9–14.7) 1.28 (0.85–1.92)0.2351.32 (0.88–2.00)0.183
  Quebec63410.5 (8.1–12.9) 1.12 (0.76–1.65)0.5531.17 (0.79–1.74)0.440
  Ontario40116.7 (13.1–20.2) 1.91 (1.28–2.84)0.0012.13 (1.42–3.21)<0.001
  Manitoba48617.9 (14.4–21.3) 2.08 (1.41–3.06)<0.0012.31 (1.55–3.45)<0.001
  Saskatchewan49111.0 (8.2–13.8) 1.18 (0.78–1.79)0.4391.29 (0.84–1.96)0.241
  Alberta55615.9 (12.9–19.0) 1.81 (1.25–2.63)0.0022.01 (1.36–2.97)<0.001
  British Columbia47317.6 (14.1–21.0) 2.03 (1.38–2.99)<0.0012.33 (1.56–3.49)<0.001
  Territories65612.7 (11.2–14.2) 1.39 (0.99–1.94)0.0551.59 (1.12–2.25)0.010
Born outside Canada       
  No507614.7 (13.2–16.2) Reference   
  Yes46412.3 (8.4–16.2) 0.93 (0.62–1.38)0.704  
Education of responding parent 0.0 (0.0–0.0)     
  Secondary or less187811.9 (9.7–14.2) 0.60 (0.44–0.81)0.0010.61 (0.43–0.87)0.006
  Post-secondary197014.4 (11.9–16.9) 0.74 (0.56–0.99)0.0410.69 (0.51–0.92)0.013
  University graduate157818.5 (15.5–21.5)   Reference 
Total household income       
  0 - $19,9993509.8 (5.3–14.4)A0.57 (0.33–0.98)0.0430.73 (0.39–1.36)0.326
  $20,000 - $39,99974411.9 (8.4–15.4) 0.70 (0.48–1.04)0.0770.89 (0.58–1.35)0.577
  $40,000 - $59,00077313.2 (9.3–17.2) 0.79 (0.54–1.16)0.2380.98 (0.64–1.50)0.920
  $60,000 - $79,99982415.4 (11.5–19.3) 0.95 (0.67–1.33)0.7471.07 (0.74–1.53)0.720
  $80,000 or more290416.1 (13.9–18.3) Reference Reference 
Country of birth of responding parent       
  Canada454714.9 (13.1–16.6) Reference Reference 
  Americas (outside Canada)18116.8 (8.6–25.0)A1.16 (0.62–2.17)0.6501.13 (0.59–2.17)0.719
  Europe16825.4 (15.7–35.0)A1.95 (1.13–3.36)0.0161.67 (0.94–2.95)0.079
  Africa10416.7 (7.6–25.8)A1.15 (0.56–2.36)0.7001.11 (0.52–2.36)0.787
  Asia4569.4 (5.9–12.8)A0.59 (0.38–0.92)0.0200.47 (0.29–0.77)0.003
  Oceania/other/not stated/ respondent not a parent139 0.27 (0.07–0.97)0.0450.49 (0.12–1.93)0.308

Rates and odds ratios are weighted (see methods)

Adjusted OR: adjusted for all variables shown in the column

A: coefficient of variation between 16.5% and 33%; interpret with caution – Unreliable estimate because coefficient of variation >33%

Association between sociodemographic variables and parental refusal of HPV vaccination in 12–14-year girls, Canada, 2013. Rates and odds ratios are weighted (see methods) Adjusted OR: adjusted for all variables shown in the column A: coefficient of variation between 16.5% and 33%; interpret with caution – Unreliable estimate because coefficient of variation >33% Socio-demographic determinants of parental refusal of the vaccine differed from those of non-vaccination. Parents living in Newfoundland and Labrador, Ontario, Manitoba, Alberta, British Columbia or the territories (compared to Nova Scotia) and those with higher educational attainment were more likely to have refused the vaccine, whereas responding parents born in Asia (compared to Canada) were significantly less likely to have refused it. Among parents who refused the HPV vaccine for their daughter, the main reasons given were concerns about vaccine safety (44.2%, 95% CI 38.6–49.8), and not considering the vaccine necessary (30.4%, 95% CI 25.2–35.6). All parents were asked general questions about their knowledge, attitudes and beliefs about vaccines. Beliefs that vaccines are safe, effective, and important for health, were associated with lower odds of HPV vaccine refusal, while concern about vaccine side-effects and the belief that alternative practices can replace vaccines were associated with higher odds of refusal (Table 3). Understanding how vaccines work, the belief that a vaccine can give the same disease it is meant to prevent, and feeling that they had enough information about immunization were not associated with HPV vaccine refusal.
Table 3.

Association between knowledge, attitudes and beliefs, and parental refusal of HPV vaccination in 12–14-year girls, Canada, 2013.

 nRate (95% CI)Unadjusted OR (95% CI)p
TOTAL    
Childhood vaccines are safe    
  Strongly agree345311.2 (9.4–12.9)0.26 (0.17–0.40)<0.001
  Somewhat agree179217.5 (14.9–20.2)0.44 (0.28–0.68)<0.001
  Somewhat/strongly disagree23832.6 (23.8–41.3)Reference 
Childhood vaccines are effective    
  Strongly agree379812.6 (10.9–14.3)0.31 (0.18–0.52)<0.001
  Somewhat agree151217.7 (14.7–20.7)0.46 (0.27–0.78)0.005
  Somewhat/strongly disagree14432.0 (21.3–42.7)Reference 
Childhood vaccines are important for child's health    
  Strongly agree420111.4 (9.9–13.0)0.24 (0.14–0.40)<0.001
  Somewhat agree114421.7 (18.2–25.3)0.51 (0.31–0.86)0.011
  Somewhat/strongly disagree14935.2 (24.5–45.8)Reference 
In general, (I) understand how vaccines work    
  Strongly agree359915.0 (13.2–16.8)1.92 (0.65–5.64)0.237
  Somewhat agree174214.7 (12.0–17.4)1.87 (0.64–5.50)0.255
  Somewhat/strongly disagree153Reference 
In general, (I am) concerned about the potential side effects of vaccnes    
  Strongly agree171819.9 (16.8–22.9)2.47 (1.53–3.99)<0.001
  Somewhat agree209515.7 (13.3–18.2)1.87 (1.17–2.96)0.008
  Somewhat disagree8936.7 (4.1–9.3)0.72 (0.39–1.31)0.281
  Strongly disagree7659.1 (5.6–12.6)Reference 
In general, a vaccine can give a serious case of the very same disease it is meant to prevent    
  Strongly agree58316.8 (12.0–21.7)1.34 (0.87–2.06)0.185
  Somewhat agree135114.5 (11.7–17.4)1.13 (0.80–1.58)0.494
  Somewhat disagree161616.2 (13.4–19.0)1.28 (0.93–1.75)0.129
  Strongly disagree152813.1 (10.4–15.9)Reference 
In general, the use of alternative practices, such as homeopathy or chiropractics, can eliminate the need for vaccination,    
  Strongly agree23216.3 (9.1–23.5)1.30 (0.74–2.29)0.365
  Somewhat agree64520.6 (15.6–25.5)1.73 (1.23–2.45)0.002
  Somewhat disagree133916.0 (13.0–19.0)1.28 (0.96–1.70)0.094
  Strongly disagree274213.0 (11.1–15.0)Reference 
(I) feel (I) have enough information about immunization    
  No94614.8 (11.3–18.3)1.00 (0.73–1.37)0.991
  Yes450314.8 (13.1–16.4)Reference 

Rates and odds ratios are weighted

A: Coefficient of variation between 16.5 and 33.3%; interpret with caution –: Unreliable estimate because coefficient of variation equal to or greater than 33.3%

Association between knowledge, attitudes and beliefs, and parental refusal of HPV vaccination in 12–14-year girls, Canada, 2013. Rates and odds ratios are weighted A: Coefficient of variation between 16.5 and 33.3%; interpret with caution –: Unreliable estimate because coefficient of variation equal to or greater than 33.3%

Discussion

This analysis of a large, nationally representative, cross–sectional survey found significant differences across provinces and territories with respect to non-immunization and refusal of the HPV vaccine among Canadian adolescent girls. Overall 27.7% of girls aged 12–14 y in 2013 had not received any doses of the HPV vaccine despite the presence of school-based HPV vaccine delivery in all Canadian provinces and territories since 2010, and 14.4% of parents reported having refused the HPV vaccine for their daughter. The factors associated with non-vaccination and HPV vaccine refusal differed. There was considerable variation in non-vaccination across the country. Girls residing in the Northwest Territories and Nunavut were the most likely (almost half) to be unvaccinated. The higher proportions of non-vaccination may be explained in part by the timing of HPV program introduction. The HPV program began in 2009–2010 in the territories (Yukon, Northwest Territories and Nunavut) as opposed to 2007–2008 in the provinces. Refusal of the HPV vaccine in the territories did not differ significantly from the provinces (with the exception of Newfoundland and Labrador), suggesting that the high proportion of unvaccinated girls in the territories was not fully explained by vaccine refusal. Although there have been a handful of Catholic school boards across Canada who have refused to allow public health delivery of the HPV vaccine within their schools over the period of time captured by the survey, these have been scattered geographically and are not felt to explain the provincial/territorial variability observed. The estimated rate of non-vaccination in British Columbia (32.4%) is close to that reported from a survey conducted in this province (35%) using a similar definition for vaccination, i.e., receiving at least one dose of the vaccine. The estimated rate of parental refusal of the vaccine in Quebec (10.5%) is similar to what was reported by another study in that province (12%). Results from Ontario and Prince Edward Island cannot be compared to those previously published from these jurisdictions because of differences in data collection methods and definitions. HPV vaccine refusal ranged from 2.9 to 17.9% across provinces and territories. Active refusal of HPV vaccine by parents was higher among those who had graduated from university compared to those with secondary or less education, and lower in those born in Asia compared to Canada. Not surprisingly, having positive attitudes about vaccines in general, such as believing they are safe, effective, and important for health were associated with lower odds of HPV vaccine refusal whereas concerns about potential side effects of vaccines in general were associated with a higher risk of refusal. It has been shown previously that general attitudes toward vaccines are significant predictors of the uptake of HPV vaccine. Higher vaccine refusal rates among parents with higher educational attainment is consistent with a study of HPV vaccine acceptance from British Columbia and with results from the National Immunization Survey-Teen in the United States. However, this pattern has not been consistently observed, as a recent meta-analysis found no association between HPV vaccine refusal and education. We did not find an association between income and vaccine refusal, contrary to a recent study from Ontario using administrative data which found that living in a higher deprivation area was associated with a lower risk of having received zero doses of vaccine. The relationship between socioeconomic status, parental educational attainment and HPV vaccine acceptance remains unclear, with studies showing both positive and negative associations. Girls whose responding parent was born in Europe or in a country within the Americas aside from Canada had significantly higher rates of non-vaccination, but not of vaccine refusal, compared to those whose responding parent was born in Canada. In contrast, parents born in Asia had a significantly lower rate of vaccine refusal than those born in Canada, but with no difference in the rate of non-vaccination among their daughters. The discrepancies between estimates of HPV non-vaccination and vaccine refusal is one of the most striking findings from this study. Among parents of girls who had never been vaccinated against HPV, less than half had refused the HPV vaccine for their daughter. There are several possible explanations for the discrepancy between uptake and refusal. This difference may be true or artifactual. If the difference is true, it may reflect the influence of factors other than parental acceptance of the vaccine such as access to immunization services, or vaccine refusal by the adolescent girl herself at the time of immunization, or absence from school on the day of a scheduled school-based immunization clinic. In contrast, an artifactual difference may reflect incomplete data within parent-held immunization records for vaccines delivered at school and/or parent's lack of recall of having consented to vaccination leading to responding no to the question on HPV vaccination. The fact that some girls had been vaccinated against HPV while their responding parent or guardian had refused the vaccine may be because consent was given by the girl's other parent or by the girl herself. In all Canadian provinces and territories, with the exception of Quebec, a young person's ability to understand the nature and consequences of a proposed medical treatment form the basis for consent to treatment, rather than reaching the age of majority. In Quebec, the Civil Code establishes the age of consent to be at 14 y. That said, a recent process evaluation of Ontario's school-based HPV program found variability in the extent to which public health nurses would accept consent from the adolescent directly (in the absence of parental consent). An alternate explanation for the discrepancy is that respondents may have changed their minds after initially refusing the vaccine, as they were asked if they had “ever” refused a vaccine for their daughter. This study is the largest assessment of HPV vaccine uptake conducted in Canada to date. However, there are limitations to consider (in addition to the consent-related issues noted above). Data were primarily collected from parents or guardians' recall and from immunization records they held, which may under-estimate vaccine coverage. However, the extent of under-estimation was mitigated using health care provider information to complement parental information for one third of participants. Knowledge and attitude questions were about vaccines in general, and would not have captured attitudes related specifically to the HPV vaccine, e.g., parents believing that the HPV vaccine is less safe or less useful than vaccines in general. In conclusion, rates of HPV non-vaccination and of refusal of the HPV vaccine are different, and are influenced by different sets of variables. The rate of HPV vaccine refusal is also higher in those who are more educated. These findings warrant further investigation in order to inform the development of targeted intervention.

Methods

The childhood national immunization coverage survey

The 2013, Childhood National Immunization Coverage Survey (CNICS) was conducted by Statistics Canada on behalf of the Public Health Agency of Canada. It was a cross-sectional survey of Canadian children aged 2, 7 or 17, plus girls 12–14 y of age (for HPV vaccine only) on March 1, 2013. Participants were randomly selected from the list of children whose parent or guardian applied for the Canadian Child Tax Benefit (CCTB), which is estimated to cover 96% of Canadian children. People living on First Nation reserves were excluded. Parents or guardians of total of 24,651 children agreed to participate in the survey. Data collection took place between September 16, 2013 and March 14, 2014 using computer-assisted telephone interviews. This analysis examined data from the sample of 12- to 14-year-old females. For the province of Ontario, only girls aged 13–14 y were included in the analysis as school-based HPV immunization starts in grade 8, making some 12-year-old girls not yet eligible for the vaccine. Parents or guardians (respondents) were asked about their child's immunization history and about their own knowledge, attitudes and beliefs relative to immunization, as well as socio-demographic information such as household income, education, and place of birth. Respondents were asked if their child had ever received any immunization. If the answer was yes, they were asked if they had the child's immunization card or booklet. If yes (58.3% of participants), the interviewer guided them through the card or booklet and recorded all immunizations received by the child. If parents had no immunization record for the child or if HPV was not recorded in it, parents were asked if their child had ever received the HPV vaccine. If a girl did not have a dose of the HPV vaccine recorded and parents responded that she had not received one, she was considered as non-vaccinated against HPV for the purposes of these analyses. If consent was given, Statistics Canada contacted health care provider(s) who had given immunizations to the child to collect data from their records. Health care provider information was available for approximately 31% of participants. Girls were considered to have received a dose of the HPV vaccine if it was reported by either their parent or healthcare provider. Parents were also asked if they had ever decided not to give a vaccine to their child and if so, to specify which vaccines(s) they had refused and why they refused these specific vaccines. Those who listed HPV as one of the vaccines they decided not to give were considered as having refused HPV vaccination for their daughter. To assess knowledge, attitudes and beliefs about vaccines, parents were asked whether they strongly agree, somewhat agree, somewhat disagree or strongly disagree to a series of statements. In some cases the “somewhat” and “strongly disagree” response categories were combined due to small numbers. Parents were also asked whether they believed they had enough information about immunization. Among variables analyzed, only household income was imputed and this was done using the nearest-neighbor imputation method. Income was imputed for 30.8% of participants.

Data analysis

Data was analyzed using SAS 9.3 (Cary, NC). Survey sampling weights were applied so that the analyses would be representative of the Canadian population of children in the target age range. Frequencies and cross-tabulations were used to estimate prevalence and examine characteristics associated with HPV non-vaccination and vaccine refusal. Logistic regressions were used to calculate unadjusted and adjusted odds ratios. For most socio-demographic dependent variables, the category with the lowest rate of non-vaccination or refusal was used as reference in logistic regressions; exceptions were countries of birth of children and responding parent, for which Canada was always used as a reference, and province or territory in the analysis of non-vaccination, where Prince Edward Island was used instead of Newfoundland because the latter appeared as an outlier. Non-responses were always included in logistic regression analyses as a separate category (in some instances merged with response categories too small to be analyzed, e.g., Oceania as a birth place). For knowledge, attitudes and belief statements, those who responded “somewhat disagree” (or strongly or somewhat disagree when small numbers obliged us to combine the categories) were used as reference, regardless of the direction of association. Independent variables with p<0.1 in simple regression models were included in multiple regressions. To account for the complex survey design, standard errors, coefficients of variation and confidence intervals were estimated with the bootstrap technique. The statistical significance level was set at <0.05.

Ethics

CNICS was conducted by Statistics Canada as part of its mandate to “collect, compile, analyze, abstract and publish statistical information relating to the commercial, industrial, financial, social, economic and general activities and conditions of the people of Canada,” and was not therefore considered as health research. The survey was done on a voluntary basis and data were kept confidential. Authors of this study had no access to any identifiable record.
  17 in total

Review 1.  "HPV? Never heard of it!": a systematic review of girls' and parents' information needs, views and preferences about human papillomavirus vaccination.

Authors:  Maggie Hendry; Ruth Lewis; Alison Clements; Sarah Damery; Clare Wilkinson
Journal:  Vaccine       Date:  2013-09-09       Impact factor: 3.641

2.  Citizen intervention in a religious ban on in-school HPV vaccine administration in Calgary, Canada.

Authors:  Juliet R Guichon; Ian Mitchell; Patricia Buffler; Art Caplan
Journal:  Prev Med       Date:  2013-06-13       Impact factor: 4.018

Review 3.  Variance estimation for complex surveys using replication techniques.

Authors:  K F Rust; J N Rao
Journal:  Stat Methods Med Res       Date:  1996-09       Impact factor: 3.021

4.  Human papillomavirus vaccine uptake in boys and girls in a school-based vaccine delivery program in Prince Edward Island, Canada.

Authors:  Carol A McClure; Mary-Ann MacSwain; Heather Morrison; Carolyn J Sanford
Journal:  Vaccine       Date:  2015-02-27       Impact factor: 3.641

5.  Ontario's school-based HPV immunization program: school board assent and parental consent.

Authors:  Sarah E Wilson; Emily Karas; Natasha S Crowcroft; Erika Bontovics; Shelley L Deeks
Journal:  Can J Public Health       Date:  2012 Jan-Feb

6.  Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results.

Authors:  Andrea Krawczyk; Bärbel Knäuper; Vladimir Gilca; Eve Dubé; Samara Perez; Keven Joyal-Desmarais; Zeev Rosberger
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  The epidemiology of genital human papillomavirus infection.

Authors:  Helen Trottier; Eduardo L Franco
Journal:  Vaccine       Date:  2006-03-30       Impact factor: 3.641

Review 8.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2015-03-03       Impact factor: 25.071

Review 9.  Inequalities in the uptake of human papillomavirus vaccination: a systematic review and meta-analysis.

Authors:  Harriet Fisher; Caroline L Trotter; Suzanne Audrey; Kyle MacDonald-Wallis; Matthew Hickman
Journal:  Int J Epidemiol       Date:  2013-04-25       Impact factor: 7.196

10.  National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years--United States, 2013.

Authors:  Laurie D Elam-Evans; David Yankey; Jenny Jeyarajah; James A Singleton; Robinette C Curtis; Jessica MacNeil; Susan Hariri
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-25       Impact factor: 17.586

View more
  9 in total

1.  "It takes time to build trust": a survey Ontario's school-based HPV immunization program ten years post-implementation.

Authors:  Eve Dubé; Sarah Wilson; Dominique Gagnon; Shelley L Deeks; Vinita Dubey
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

Review 2.  No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Authors:  Thomas C Mitchell; Carolyn R Casella
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

3.  Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study.

Authors:  Samara Perez; Ovidiu Tatar; Gilla K Shapiro; Eve Dubé; Gina Ogilvie; Juliet Guichon; Vladimir Gilca; Zeev Rosberger
Journal:  BMC Public Health       Date:  2016-12-05       Impact factor: 3.295

4.  Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response.

Authors:  Chun-Lan Zhuang; Zhi-Jie Lin; Zhao-Feng Bi; Ling-Xian Qiu; Fang-Fang Hu; Xiao-Hui Liu; Bi-Zhen Lin; Ying-Ying Su; Hui-Rong Pan; Tian-Ying Zhang; Shou-Jie Huang; Yue-Mei Hu; You-Lin Qiao; Feng-Cai Zhu; Ting Wu; Jun Zhang; Ning-Shao Xia
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

5.  Investigating Canadian parents' HPV vaccine knowledge, attitudes and behaviour: a study protocol for a longitudinal national online survey.

Authors:  Gilla K Shapiro; Samara Perez; Anila Naz; Ovidiu Tatar; Juliet R Guichon; Rhonda Amsel; Gregory D Zimet; Zeev Rosberger
Journal:  BMJ Open       Date:  2017-10-11       Impact factor: 2.692

6.  Comparing human papillomavirus vaccine concerns on Twitter: a cross-sectional study of users in Australia, Canada and the UK.

Authors:  Gilla K Shapiro; Didi Surian; Adam G Dunn; Ryan Perry; Margaret Kelaher
Journal:  BMJ Open       Date:  2017-10-05       Impact factor: 2.692

7.  Validation of the vaccine conspiracy beliefs scale.

Authors:  Gilla K Shapiro; Anne Holding; Samara Perez; Rhonda Amsel; Zeev Rosberger
Journal:  Papillomavirus Res       Date:  2016-09-30

8.  Delayed measles vaccination of toddlers in Canada: Associated socio-demographic factors and parental knowledge, attitudes and beliefs.

Authors:  Simone Périnet; Marilou Kiely; Gaston De Serres; Nicolas L Gilbert
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

9.  Evolution of Public Health Human Papillomavirus Immunization Programs in Canada.

Authors:  Alexandra Goyette; Glorian P Yen; Voica Racovitan; Parambir Bhangu; Smita Kothari; Eduardo L Franco
Journal:  Curr Oncol       Date:  2021-02-22       Impact factor: 3.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.